| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2500862 | International Journal of Pharmaceutics | 2016 | 12 Pages |
Abstract
The monoclonal antibody infliximab is one of the cornerstones in the treatment of Crohn’s disease. Local delivery of infliximab would be an alternative to overcome the inherent disadvantages of intravenous therapy. For this purpose 5 mg infliximab tablets were developed. To stabilize the antibody during production and storage it was incorporated in a sugar glass containing the oligosaccharide inulin. To obtain colon-specific release a ColoPulse coating was applied. The tablets were stored for 16 months under different conditions based on ICH climatic zone I:
Graphical abstractFigure optionsDownload full-size imageDownload high-quality image (62 K)Download as PowerPoint slide
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmaceutical Science
Authors
Jacoba M. Maurer, Susan Hofman, Reinout C.A. Schellekens, Wouter F. Tonnis, Annelien O.T. Dubois, Herman J. Woerdenbag, Wouter L.J. Hinrichs, Jos G.W. Kosterink, Henderik W. Frijlink,